Longan seed-derived peptides inhibit glucose transport via modulation of SGLT1 and GLUT2 in Caco-2 cells
1
Issued Date
2026-03-01
Resource Type
eISSN
26661543
Scopus ID
2-s2.0-105029591175
Journal Title
Journal of Agriculture and Food Research
Volume
26
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Agriculture and Food Research Vol.26 (2026)
Suggested Citation
Kuptawach K., Sangtanoo P., Nutho B., Reamtong O., Srimongkol P., Karnchanatat A. Longan seed-derived peptides inhibit glucose transport via modulation of SGLT1 and GLUT2 in Caco-2 cells. Journal of Agriculture and Food Research Vol.26 (2026). doi:10.1016/j.jafr.2026.102736 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115068
Title
Longan seed-derived peptides inhibit glucose transport via modulation of SGLT1 and GLUT2 in Caco-2 cells
Corresponding Author(s)
Other Contributor(s)
Abstract
This study presents the first evidence of the ability of two synthetic peptides, SA-10 (SSYYPFKGFA) and VI-10 (VKGPGLYSDI), derived from longan seed hydrolysates to inhibit intestinal glucose absorption via SGLT1 and GLUT2 transporters. Molecular docking revealed strong binding affinities: SA-10 to SGLT1 (−9.1 kcal/mol) and VI-10 to GLUT2 (−8.7 kcal/mol), involving hydrogen bonds and hydrophobic interactions at key glucose-binding sites, suggesting competitive inhibition. Molecular dynamics simulations over 100 ns supported these findings, demonstrating structural stability and compactness of the peptide-transporter complexes, as indicated by sustained RMSD and Rg values throughout the simulation trajectory. In vitro assays using Caco-2 cells showed that both peptides significantly reduced glucose uptake in a dose- and time-dependent manner, achieving approximately 50% reduction at 1.00 mM after 3 h. Western blot analysis confirmed SA-10 downregulated SGLT1 expression, while VI-10 reduced both SGLT1 and GLUT2 levels. These findings suggest that longan seed-derived peptides can modulate both glucose uptake and transporter expression in intestinal cells. Importantly, SA-10 and VI-10 represent novel glucose transporter inhibitors and hold promise for development as functional food ingredients or nutraceuticals to manage postprandial hyperglycemia and support glycemic control in diabetes management.